Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB

Size: px
Start display at page:

Download "Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB"

Transcription

1 Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB

2 Disclosures I have only really worked with the Freelite assays Previous research funding, technical support and brief employment with The Binding Site

3 Freelite sflc in CKD why use a different reference range?

4 Freelite SFLC in CKD why use a different reference range? CKD or Renal (impairment) Reference range???

5 Freelite SFLC in CKD why use a different reference range? Why do we have a Renal reference range Biology there of Does it matter? Clinically important or a lab variable? Assay issue? Freelite vs N-latex (Siemens)

6 Free light chains (FLCs) - bi-products of intact immunoglobulin synthesis Kappa Monomeric (22.5kDa) Lambda Dimeric (45kDa)

7 FLC renal metabolism + sites of injury

8 Kinetic model of FLCs in renal failure P(t) k k 1e k d k re k 21 k re Department of engineering, University of Warwick. Hutchison et al. J Am Soc Neph 2007

9 Serum polyclonal FLC concentrations increase as GFR decreases Kappa (shaded) Lambda (clear) Both: P<0.01 cjasn

10 Serum FLC ratio increases through the CKD stages P<0.001 cjasn

11 Why FLC ratio changes? When kidneys are working well: k>l clearance When kidneys are not working: RE clearance dominates no difference (k or l) Therefore no kidneys serum ratio represents the underlying production rate k/l of 1.8

12 The advent of the Renal FLC Range Mayo normal: (in this group there will be some with renal impairment) Renal range:

13 The advent of the Renal FLC Range Mayo normal: Renal range: Abadie et al. Renal range: up to 3.1 Marshall et al. Renal range: up to 3.2 Abadie JM, Am J Clin Path Marshall G, Am J Clin Path 2009

14 The advent of the Freelite Renal FLC Range Mayo normal: Renal range: Clinically relevant???

15 Evaluated serum FLC immunoassays as a diagnostic tool in patients with severe renal failure 142 patients with new dialysis dependent renal failure Serum was screened by SPE and FLCs (IFE) Urine was analysed where available 41 patients had a clinical diagnosis of multiple myeloma BMC Nephrology

16 Serum lambda FLC (mg/l) Serum kappa FLC (mg/l) BMC Nephrology

17 ROC Normal vs Renal for Myeloma Kidney Standard (Green) New range (Blue) BMC Nephrology

18 So.. Renal reference range decreases false +ves Reduced phone calls to haematologist or the laboratory: What does a FLC ratio of 2.76 mean.. But does it change the way we practice?

19 What is the role of the FLC assay?

20 What is the role of the FLC assay? It is only ever a part of the patient work-up for?myeloma Tissue (Kidney or Marrow or both ) SPE/IFE Urine analysis Skeletal surveys etc

21 Renal range in the Real Renal World Review of the last 50 new outpatients in the renal clinic i.e. not AKI Mostly advancing CKD or proteinuria

22 FLC normal range

23 FLC ranges in clinic

24 Renal ranges.. In clinic.

25 Hawke s Bay New Patients 50 patients: egfr 31 (range 6-95) mls/min/1.73m2 Kappa 38.1 ( ) mg/l Lambda 36.1 ( ) mg/l Ratio 0.98 ( ) all polyclonals Excluded: 2 with plasma cell dyscrasias

26 Hawke s Bay New Patients Excluded: 2 with plasma cell dyscrasias Myeloma kidney: egfr 18mls/min Kappa 11,000mg/L Lambda 3.71mg/L ratio 2964 AL-amyloid: egfr 30mls/min Kappa 700mg/L Lambda 8.8mg/L ratio 80

27 Hawke s Bay New Patients 100% FLC ratio range: (polyclonals) Birmingham renal patients with plasma cell dyscrasias 2 patients with ratios outside of normal 1.76 and 1.77 so 4% of patients false +ve

28 Ratio changes with egfr

29 An assay issue Freelite vs N-latex N Latex FLC serum FLC assays in patients with renal impairment. Jacobs JF et al, Clin Chem Lab Med 2014; 52:853-9 All patients with CKD had FLC within normal ratio with N-latex But not with Freelite

30 An assay issue Freelite vs N-latex Berlanga et al Clin Chem Lab Med 2014

31 Summary of diagnostics: With Freelite the normal range does change with impaired renal function Reduced clearance better representation of underlying synthesis Unresolved differences between Freelite and N-latex

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar Serum free light chain (SFLC) assays Dr Sarah Sasson SydPath Registrar Introduction to SFLC Plasma cell dyscrasias such as monoclonal gammopathy of uncertain significance (MGUS) smouldering/asymptomatic

More information

Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Understanding the Serum Free Light Chain Assays Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. AL Amyloidosis: abnormality of proteins from Plasma Cells in the Bone Marrow Red

More information

Sheena Surindran Grand Rounds 2/15/11

Sheena Surindran Grand Rounds 2/15/11 Sheena Surindran Grand Rounds 2/15/11 Affects 5 12 person per million / year 5 10% associated with myeloma Median survival without treatment is 12 40 months Most commonly affected organs are kidney, heart

More information

Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM

Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving

More information

Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial

Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,

More information

Multiple Myeloma Advances for clinical pathologists & histopathologists

Multiple Myeloma Advances for clinical pathologists & histopathologists Multiple Myeloma Advances for clinical pathologists & histopathologists CME in Haematology 2014 IAPP & Dept of Pathology, BVDUMC, Pune Sunday, 4 th May 2014 Dr. M.B. Agarwal, MD, MNAMS Head, Dept of Haematology

More information

Geriatric Nephrology. Murtener Tage

Geriatric Nephrology. Murtener Tage Geriatric Nephrology Murtener Tage 2014 Isabelle.Binet@kssg.ch www.nierenstiftung.ch Plan Geriatric nephrology The elderly with CKD The elderly on dialysis The elderly in transplantation Plan Geriatric

More information

Malcolm P. McTaggart, PhD, 1 Jindriska Lindsay, FRCPath, 2 and Edward M. Kearney, FRCPath 1 ABSTRACT

Malcolm P. McTaggart, PhD, 1 Jindriska Lindsay, FRCPath, 2 and Edward M. Kearney, FRCPath 1 ABSTRACT Replacing Urine Protein Electrophoresis With Serum Free Light Chain Analysis as a First-Line Test for Detecting Plasma Cell Disorders Offers Increased Diagnostic Accuracy and Potential Health Benefit to

More information

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT The Kidney in Multiple Myeloma Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT Normal Cell Plasma cells produce antibodies that bind to antigens,

More information

Acute renal failure Definition and detection

Acute renal failure Definition and detection Acute renal failure Definition and detection Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM Definition Acute Renal Failure Acute Kidney Injury

More information

Professor Suetonia Palmer

Professor Suetonia Palmer Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS

More information

Jo Abraham MD Division of Nephrology University of Utah

Jo Abraham MD Division of Nephrology University of Utah Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive

More information

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME Dr Seethalekshmy N.V., Dr.Annie Jojo, Dr Hiran K.R., Amrita institute of Medical Sciences, Kochi, Kerala Case history 34 year old gentleman Nephrotic range

More information

Serum Free Light Chain Assay

Serum Free Light Chain Assay Serum Free Light Chain Assay This Infosheet explains what light chains are, what the Serum Free Light Chain Assay is, and why it is used in AL amyloidosis. In AL amyloidosis, abnormal plasma cells in the

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016 MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site

More information

Hevylite assays de - convoluted. Dr Karthik Ramasamy Oxford University Hospitals

Hevylite assays de - convoluted. Dr Karthik Ramasamy Oxford University Hospitals Hevylite assays de - convoluted Dr Karthik Ramasamy Oxford University Hospitals Overview Hevylite assay Introduction Clinical utility of Hevylite 2 Hevylite specifici.es Hevylite specifici.es Hevylite

More information

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + Disclosures Advisory Boards: AMGEN, Lundbeck, NOVARTIS + Subtypes of Plasma Cell Disorders Increased Plasma

More information

Beta-2 microglobulin and short Ig chains and organ damage in dialysis patients: An update.

Beta-2 microglobulin and short Ig chains and organ damage in dialysis patients: An update. EURECA-m CME COURSE, Cardiovascular Problems and Solutions in Chronic Kidney Disease Ankara Hilton Hotel, Ankara, September 8, 2012 Beta-2 microglobulin and short Ig chains and organ damage in dialysis

More information

Liverpool experience of Community AKI care

Liverpool experience of Community AKI care Liverpool experience of Community AKI care Shahed Ahmed Consultant Nephrologist and Honorary Lecturer Royal Liverpool University Hospital shahed.ahmed@rlbuht.nhs.uk Is AKI really a problem? 100000, deaths

More information

Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis

Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis ORIGINAL PAPERS Adv Clin Exp Med 2014, 23, 4, 531 538 ISSN 1899 5276 Copyright by Wroclaw Medical University Lidia Usnarska-Zubkiewicz 1, A, C F, Jadwiga Hołojda 2, B C, F, Jakub Dębski 3, B, Anna Zubkiewicz-Zarębska

More information

Amiloidosi AL: clinica, esami diagnostici e prognosi

Amiloidosi AL: clinica, esami diagnostici e prognosi Titolo relazione Amiloidosi AL: clinica, esami diagnostici e prognosi Giovanni Palladini Amyloidosis: protein misfolding disease! Titolo relazione Clinical presentation of the most common forms of Titolo

More information

Adding Insult to Injury. Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London

Adding Insult to Injury. Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London Acute Kidney Injury Adding Insult to Injury Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London Content 1. Brief review of AKI and its impact 2. Comments on the

More information

Plasma cell dyscrasia with renal impairment including MGRS

Plasma cell dyscrasia with renal impairment including MGRS Plasma cell dyscrasia with renal impairment including MGRS ~ The importance of multi-departmental management ~ Dept. Nephrology, Japan Community Health Care Organization Sendai Hospital Shinichi Mizuno

More information

CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations

CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations Malaysian J Pathol 2017; 39(3) : 311 315 CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations Siti Yazmin ZAHARI SHAM BM, MPath, Subashini C. THAMBIAH MBBS, MPath,

More information

Cystatin C: A New Approach to Improve Medication Dosing

Cystatin C: A New Approach to Improve Medication Dosing Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery

More information

Biomarkers for the Prevention of Drug Induced AKI (D-AKI)

Biomarkers for the Prevention of Drug Induced AKI (D-AKI) Biomarkers for the Prevention of Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist, UPMC OBJECTIVE

More information

5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors.

5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors. Overview The Kidneys Nicola Barlow Clinical Biochemistry Department City Hospital Renal physiology Renal pathophysiology Acute kidney injury Chronic kidney disease Assessing renal function GFR Proteinuria

More information

Las dos caras de la cretinina sérica The two sides of serum creatinine

Las dos caras de la cretinina sérica The two sides of serum creatinine Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1

More information

Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease

Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease International Rheumatology Volume 2013, Article ID 426759, 6 pages http://dx.doi.org/10.1155/2013/426759 Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease Aurélie

More information

Multiple Myeloma 101: Understanding Your Labs

Multiple Myeloma 101: Understanding Your Labs Multiple Myeloma 101: Understanding Your Labs Tim Wassenaar MD MS Hematologist, Director of Clinical Trials UW Cancer Center at ProHealth Care None Disclosures Outline Define hematopoiesis WBCs, RBCs,

More information

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance S. Vincent

More information

Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis

Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis ORIGINAL ARTICLE Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis Masayuki MATSUDA, Toshiyuki YAMADA**, Takahisa GONO, Yasuhiro SHIMOJIMA, Wataru ISHII,

More information

Identifying and Managing Chronic Kidney Disease: A Practical Approach

Identifying and Managing Chronic Kidney Disease: A Practical Approach Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,

More information

Amyloidosis: What to do and how to diagnose: An Update 2017

Amyloidosis: What to do and how to diagnose: An Update 2017 Amyloidosis: What to do and how to diagnose: An Update 2017 Jonathan L. Kaufman, MD Associate Professor Hematology & Oncology Winship Cancer Institute of Emory University Amyloidosis Protein Conformation/Deposition

More information

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305

More information

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,

More information

Cystatin C (serum, plasma, urine)

Cystatin C (serum, plasma, urine) Cystatin C (serum, plasma, urine) 1 Name and description of analyte 1.1 Name of analyte Cystatin C (serum, plasma and urine) 1.2 Alternative names Cystatin 3, post-gamma-globulin, neuroendocrine basic

More information

Composite Performance Report

Composite Performance Report Composite Performance Report 10 9 91% 8 7 65% 68% 65% 6 56% 5 4 3 2 44% 37% 48% 31% 19% 29% 1 6% Key: Report Measure Name Cohort Target Cohort Definition Formula 1 Control Blood Pressure All patients who

More information

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National

More information

THE CONSERVATIVE CARE PATHWAY

THE CONSERVATIVE CARE PATHWAY THE CONSERVATIVE CARE PATHWAY Dr. Gaylene Hargrove Sept. 19, 2015 Island Health Renal Program End of Life Conference Learning Objectives Describe and discuss what defines conservative care. Identify key

More information

NGAL, a new markers for acute kidney injury

NGAL, a new markers for acute kidney injury NGAL, a new markers for acute kidney injury Prof. J. Delanghe, MD, PhD Dept. Clinical Chemistry Ghent University Lecture Feb 8, 2011 Serum creatinine is an inadequate marker for AKI. > 50% of renal

More information

Faculty/Presenter Disclosure

Faculty/Presenter Disclosure CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO

More information

Laboratory Examination

Laboratory Examination Todd Zimmerman, M.D. 64 year old African American male presents to establish care with PCG. Meds: Norvasc 5 mg daily PMHx: HTN x 20 years, poorly controlled SHx: No tobacco, illicit; rare EtOH ROS: Negative

More information

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and

More information

Clinical Pearls in Renal Medicine

Clinical Pearls in Renal Medicine Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have

More information

THE KIDNEY AND SLE LUPUS NEPHRITIS

THE KIDNEY AND SLE LUPUS NEPHRITIS THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS

More information

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function

More information

Translating the KidneyWise Clinical Toolkit into an Electronic Medical Record Decision Support Tool

Translating the KidneyWise Clinical Toolkit into an Electronic Medical Record Decision Support Tool Translating the KidneyWise Clinical Toolkit into an Electronic Medical Record Decision Support Tool An Innovative and Practical Strategy for Primary Care Providers Dr. Allan Grill, CCO-Ontario Renal Network

More information

Screening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!

Screening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen

More information

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able

More information

Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance)

Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance) Southern Derbyshire Shared Care Pathology Guidelines MGUS (Monoclonal Gammopathy of Undetermined Significance) Purpose of guideline This guideline provides information about the risk stratification of

More information

Suspecting Tumors, or Could it be cancer?

Suspecting Tumors, or Could it be cancer? Suspecting Tumors, or Could it be cancer? Donna E. Reece, M.D. Princess Margaret Cancer Centre University Health Network Toronto, ON CANADA 07 February 2018 Background Low back pain is common However,

More information

PHA First Exam. Fall 2004

PHA First Exam. Fall 2004 PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem

More information

Hevylite : a New Serum Test for Assessing Patients with Multiple Myeloma

Hevylite : a New Serum Test for Assessing Patients with Multiple Myeloma Hevyite : a New Serum Test for Assessing Patients with Mutipe Myeoma Judith A. Finay, Ph.D. Director of Scientific Affairs The Binding Site, Inc. San Diego, CA 800-633-4484 X335 Some of the subject matter

More information

The Health Problem: Guidelines: NHS Priority:

The Health Problem: Guidelines: NHS Priority: PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation research project.

More information

HUGE EQUATION ACCURACY FOR SCREENING CHRONIC KIDNEY DISEASE: A PROSPECTIVE STUDY

HUGE EQUATION ACCURACY FOR SCREENING CHRONIC KIDNEY DISEASE: A PROSPECTIVE STUDY Journal of Aging Research & Clinical Practice Volume 6, 2017 J Aging Res Clin Practice 2017;inpress Published online in press HUGE EQUATION ACCURACY FOR SCREENING CHRONIC KIDNEY DISEASE: A PROSPECTIVE

More information

Pro-enkephalin and Renal Disease. Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease

Pro-enkephalin and Renal Disease. Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease Pro-enkephalin and Renal Disease Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease The presenter has received relevant grants and /or consulting

More information

Interesting case seminar: Native kidneys Case Report:

Interesting case seminar: Native kidneys Case Report: Interesting case seminar: Native kidneys Case Report: Proximal tubulopathy and light chain deposition disease presented as severe pulmonary hypertension with right-sided cardiac dysfunction and nephrotic

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

Forms Revision: Myeloma Changes

Forms Revision: Myeloma Changes Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.

More information

Urinary biomarkers in acute kidney injury. Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet

Urinary biomarkers in acute kidney injury. Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet Urinary biomarkers in acute kidney injury Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet Development of AKI-biomarkers Early markers of AKI, do we need them? GFR drop Normal

More information

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3) (Form 2116 Revision 3) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Plasma Cell Disorders (PCD) Post-HCT Data Form. E-mail comments regarding the

More information

GFR and Drug Dosage Adaptation: Are We still in the Mist?

GFR and Drug Dosage Adaptation: Are We still in the Mist? GFR and Drug Dosage Adaptation: Are We still in the Mist? Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM I have no conflict of interest to declare

More information

Acute Kidney Injury Care in the Chronic Unit

Acute Kidney Injury Care in the Chronic Unit Acute Kidney Injury Care in the Chronic Unit BONNIE B GREENSPAN WITH ASSIST FROM: DENISE MURCEK, JINA BOGLE, MARY SCHIRA, OCTOBER 5, 2017 Objectives At the completion of the session, engaged participants

More information

Michael Joffe ST6 Haematology SpR

Michael Joffe ST6 Haematology SpR Michael Joffe ST6 Haematology SpR Mrs SB 71 year old female on AMU Telephone referral to haematology by medicine with Hb 102 MCV 89, normal B12, Folate, Ferritin. PMH DM General decline over several weeks

More information

Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham

Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure

More information

Caring for the AKI Survivor: What is Required?

Caring for the AKI Survivor: What is Required? Caring for the AKI Survivor: What is Required? Ron Wald, MDCM MPH FRCPC Division of Nephrology St. Michael s Hospital and University of Toronto February 28, 2019 A patient in your ICU 65M with DM, HTN,

More information

RCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem?

RCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem? RCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem? Lui G Forni : Consultant Intensivist & Nephrologist Faculty of Health Sciences : University of Surrey Disclosures Research Funding

More information

Masatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health

Masatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health 176 J Occup Health, Vol. 54, 2012 J Occup Health 2012; 54: 176 180 Journal of Occupational Health Evaluation of Validity of the Urine Dipstick Test for Identification of Reduced Glomerular Filtration Rate

More information

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona Málaga, 16 de noviembre

More information

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,

More information

Making possible personal.

Making possible personal. Making possible personal. HDX THERAPY, ENABLED BY THE THERANOVA DIALYZER HDF PERFORMANCE AND BEYOND AS SIMPLE AS HD The THERANOVA dialyzer, featuring an innovative membrane, effectively targets large middle

More information

Section Questions Answers

Section Questions Answers Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension

More information

Chronic renal disease in the elderly: are all pigs to be considered equal?

Chronic renal disease in the elderly: are all pigs to be considered equal? Chronic renal disease in the elderly: are all pigs to be considered equal? W. Van Biesen, Ghent University Hospital Elwood et al, cjasn, 2013 Elderly and CKD: a thematic synthesis Overview CKD in the

More information

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015 Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the

More information

Chronic kidney disease (CKD) (Southampton pathway)

Chronic kidney disease (CKD) (Southampton pathway) Background information Patient information Key messages for this pathway Definitions and abbreviations used in this pathway Classification of CKD Diagnosis of CKD Summary of referral criteria Screening

More information

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage

More information

Case Studies: Renal and Urologic Impairments Workshop

Case Studies: Renal and Urologic Impairments Workshop Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case

More information

The Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD

The Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD The Link Between Acute and Chronic Kidney Disease John Arthur, MD, PhD Conventional Dogma Conventional dogma was that if a patient survived and recovered from AKI, he was unlikely to have long-term sequela.

More information

Assessing Renal Function: What you Didn t Know You Didn t Know

Assessing Renal Function: What you Didn t Know You Didn t Know Assessing Renal Function: What you Didn t Know You Didn t Know Presented By Tom Wadsworth PharmD, BCPS Associate Clinical Professor UAA/ISU Doctor of Pharmacy Program Idaho State University College of

More information

Office Management of Reduced GFR Practical advice for the management of CKD

Office Management of Reduced GFR Practical advice for the management of CKD Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE

More information

International Journal of Pharma and Bio Sciences IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS?

International Journal of Pharma and Bio Sciences IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS? International Journal of Pharma and Bio Sciences RESEARCH ARTICLE BIO CHEMISTRY IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS? Corresponding Author R.KUMARESAN Department

More information

CKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral

CKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral CKD IN THE CLINIC Family Physician Refresher Course Lisa M. Antes, MD April 19, 2017 No disclosures Session Content 1. 2. Recommendations for commonly used medications in CKD Basic principles /patient

More information

The role of the Nephrologist in Acute Kidney Injury. Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital

The role of the Nephrologist in Acute Kidney Injury. Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital The role of the Nephrologist in Acute Kidney Injury Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital Overview Impact of AKI Need for change Who needs a Nephrologist Are we making

More information

CKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry. UK Renal Registry 2013 Annual Audit Meeting

CKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry. UK Renal Registry 2013 Annual Audit Meeting CKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry UK Renal Registry 2013 Annual Audit Meeting Scope of the talk Background CK MAPPS EQUAL My Research Future

More information

Screening for Chronic Kidney Disease: Time to Say No

Screening for Chronic Kidney Disease: Time to Say No Screening for Chronic Kidney Disease: Time to Say No Charles P. Vega, MD Disclosures February 27, 2014 Introduction Chronic kidney disease (CKD) is common and often asymptomatic at the time of diagnosis.

More information

CKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS

CKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS CKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS PLoS One. 2014 Nov 26;9(11):e110535. Of the 445 PCPs who enrolled at least 10 patients, 19 (4.3%) had >50% likelihood

More information

Using the Knowledge to Action Cycle to Improve Timing of dialysis initiation

Using the Knowledge to Action Cycle to Improve Timing of dialysis initiation Using the Knowledge to Action Cycle to Improve Timing of dialysis initiation Braden Manns University of Calgary Funded by The Kidney Foundation of Canada and the Canadian Institutes of Health Research

More information

Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI)

Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI) Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist,

More information

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure. Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test

More information

The ABCs of Waldenström s Macroglobulinemia (WM)

The ABCs of Waldenström s Macroglobulinemia (WM) The ABCs of Waldenström s Macroglobulinemia (WM) Jeffrey V. Matous MD Colorado Blood Cancer Institute IWMF Ed Forum May 2017 Objectives Describe the roots underneath WM Review incidence, possible risk

More information

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress

More information

The evidence base for interventions to slow the progression of chronic kidney disease: Medical interventions. Jonathan Evans Paediatric Nephrologist

The evidence base for interventions to slow the progression of chronic kidney disease: Medical interventions. Jonathan Evans Paediatric Nephrologist The evidence base for interventions to slow the progression of chronic kidney disease: Medical interventions Jonathan Evans Paediatric Nephrologist CKD in adults Often unrecognised Preventable Major cardiovascular

More information

Primary Care Approach to Management of CKD

Primary Care Approach to Management of CKD Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low

More information

The Pursuit of Prevention of Renal failure in an imperfect world-is it possible in the 21 st century?

The Pursuit of Prevention of Renal failure in an imperfect world-is it possible in the 21 st century? The Pursuit of Prevention of Renal failure in an imperfect world-is it possible in the 21 st century? By: Baskar, WDHB, Renal Service Auckland New Zealand Presented at : 4 th International Conference on

More information

Diabetic Kidney Disease in the Primary Care Clinic

Diabetic Kidney Disease in the Primary Care Clinic Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney

More information

Management of Multiple Myeloma

Management of Multiple Myeloma Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.

More information

Pathology of Complement Mediated Renal Disease

Pathology of Complement Mediated Renal Disease Pathology of Complement Mediated Renal Disease Mariam Priya Alexander, MD Associate Professor of Pathology GN Symposium Hong Kong Society of Nephrology July 8 th, 2017 2017 MFMER slide-1 The complement

More information

Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report

Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report Case Reports in Nephrology Volume 2012, Article ID 593460, 4 pages doi:10.1155/2012/593460 Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion:

More information

Amyloidosis and Waldenström s Macroglobulinemia

Amyloidosis and Waldenström s Macroglobulinemia Amyloidosis and Waldenström s Macroglobulinemia Morie A. Gertz, Giampaolo Merlini, and Steven P. Treon Primary systemic amyloidosis is an immunoglobulin light chain disorder that is 1/5th as common as

More information